These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 18097006)

  • 1. Immunotherapy with chimeric NKG2D receptors leads to long-term tumor-free survival and development of host antitumor immunity in murine ovarian cancer.
    Barber A; Zhang T; Sentman CL
    J Immunol; 2008 Jan; 180(1):72-8. PubMed ID: 18097006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer.
    Barber A; Zhang T; DeMars LR; Conejo-Garcia J; Roby KF; Sentman CL
    Cancer Res; 2007 May; 67(10):5003-8. PubMed ID: 17510432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric NKG2D modified T cells inhibit systemic T-cell lymphoma growth in a manner involving multiple cytokines and cytotoxic pathways.
    Zhang T; Barber A; Sentman CL
    Cancer Res; 2007 Nov; 67(22):11029-36. PubMed ID: 18006849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chimeric NKG2D T cells require both T cell- and host-derived cytokine secretion and perforin expression to increase tumor antigen presentation and systemic immunity.
    Barber A; Sentman CL
    J Immunol; 2009 Aug; 183(4):2365-72. PubMed ID: 19625653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor.
    Zhang T; Barber A; Sentman CL
    Cancer Res; 2006 Jun; 66(11):5927-33. PubMed ID: 16740733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric NKG2D expressing T cells eliminate immunosuppression and activate immunity within the ovarian tumor microenvironment.
    Barber A; Rynda A; Sentman CL
    J Immunol; 2009 Dec; 183(11):6939-47. PubMed ID: 19915047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of Acute Toxicity in NKG2D Chimeric Antigen Receptor T Cell-Treated Mice.
    Sentman ML; Murad JM; Cook WJ; Wu MR; Reder J; Baumeister SH; Dranoff G; Fanger MW; Sentman CL
    J Immunol; 2016 Dec; 197(12):4674-4685. PubMed ID: 27849169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NKG2D CAR T-cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors.
    Spear P; Barber A; Rynda-Apple A; Sentman CL
    Immunol Cell Biol; 2013 Jul; 91(6):435-40. PubMed ID: 23628805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of multiple myeloma with adoptively transferred chimeric NKG2D receptor-expressing T cells.
    Barber A; Meehan KR; Sentman CL
    Gene Ther; 2011 May; 18(5):509-16. PubMed ID: 21209626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Augmented anti-tumor activity of NK-92 cells expressing chimeric receptors of TGF-βR II and NKG2D.
    Wang Z; Guo L; Song Y; Zhang Y; Lin D; Hu B; Mei Y; Sandikin D; Liu H
    Cancer Immunol Immunother; 2017 Apr; 66(4):537-548. PubMed ID: 28184969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy.
    Zhang T; Lemoi BA; Sentman CL
    Blood; 2005 Sep; 106(5):1544-51. PubMed ID: 15890688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor efficacy induced by human ovarian cancer cells secreting IL-21 alone or combination with GM-CSF cytokines in nude mice model.
    Dou J; Wang Y; Wang J; Zhao F; Li Y; Cao M; Hu W; Hu K; He XF; Chu L; Jiang C; Gu N
    Immunobiology; 2009; 214(6):483-92. PubMed ID: 19389515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells.
    Zhang T; Sentman CL
    Cancer Res; 2011 Mar; 71(6):2066-76. PubMed ID: 21282338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The combined actions of NK and T lymphocytes are necessary to reject an EGFP+ mesenchymal tumor through mechanisms dependent on NKG2D and IFN gamma.
    Arina A; Murillo O; Hervás-Stubbs S; Azpilikueta A; Dubrot J; Tirapu I; Huarte E; Alfaro C; Pérez-Gracia JL; González-Aseguinolaza G; Sarobe P; Lasarte JJ; Jamieson A; Prieto J; Raulet DH; Melero I
    Int J Cancer; 2007 Sep; 121(6):1282-95. PubMed ID: 17520674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mouse tumor vasculature expresses NKG2D ligands and can be targeted by chimeric NKG2D-modified T cells.
    Zhang T; Sentman CL
    J Immunol; 2013 Mar; 190(5):2455-63. PubMed ID: 23355740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NKG2D-Based CAR T Cells and Radiotherapy Exert Synergistic Efficacy in Glioblastoma.
    Weiss T; Weller M; Guckenberger M; Sentman CL; Roth P
    Cancer Res; 2018 Feb; 78(4):1031-1043. PubMed ID: 29222400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chimeric NKG2D receptor-expressing T cells as an immunotherapy for multiple myeloma.
    Barber A; Zhang T; Megli CJ; Wu J; Meehan KR; Sentman CL
    Exp Hematol; 2008 Oct; 36(10):1318-28. PubMed ID: 18599182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric antigen receptor T cells shape myeloid cell function within the tumor microenvironment through IFN-γ and GM-CSF.
    Spear P; Barber A; Rynda-Apple A; Sentman CL
    J Immunol; 2012 Jun; 188(12):6389-98. PubMed ID: 22586039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful adoptive cellular immunotherapy is dependent on induction of a host immune response triggered by cytokine (IFN-gamma and granulocyte/macrophage colony-stimulating factor) producing donor tumor-infiltrating lymphocytes.
    Nagoshi M; Goedegebuure PS; Burger UL; Sadanaga N; Chang MP; Eberlein TJ
    J Immunol; 1998 Jan; 160(1):334-44. PubMed ID: 9551989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.